<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03111394</url>
  </required_header>
  <id_info>
    <org_study_id>HS-16-00579</org_study_id>
    <nct_id>NCT03111394</nct_id>
  </id_info>
  <brief_title>Study of myMS in Participants With a Diagnosis of Multiple Sclerosis</brief_title>
  <official_title>A Pilot Study Evaluating the Feasibility of A Mobile Application to Collect Clinical, Magnetic Resonance Imaging Information and Genetic Data in Participants With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study looking at the feasibility of a mobile application (app) to collect&#xD;
      data from active tasks (questionnaires, 6Mapp™, COGapp™, VISapp™), clinical magnetic&#xD;
      resonance imaging information and conduct genome-wide association studies in subjects with&#xD;
      multiple sclerosis. Participants will be self-referred to this study from different sources;&#xD;
      patient advocacy groups, social media tools, clinicaltrials.gov, and flyers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study evaluating the feasibility of a mobile application &quot;myMS™&quot; to collect&#xD;
      active clinical tasks (questionnaires, 6Mapp™, COGapp™, VISapp™), magnetic resonance imaging&#xD;
      information and conduct genome-wide association studies in subjects with multiple sclerosis.&#xD;
      Participants will be self-referred to this study from different sources; patient advocacy&#xD;
      groups, social media tools, clinicaltrials.gov, and flyers.&#xD;
&#xD;
      Specific aims of this pilot study are:&#xD;
&#xD;
        1. To determine the feasibility and work flow in prospectively collecting surveys, clinical&#xD;
           tasks, magnetic resonance imaging (MRI) information for up to 200 self-referred adult MS&#xD;
           participants, using mobile app myMS™.&#xD;
&#xD;
        2. To determine the feasibility of using interface between myMS™ and 23andMe® DNA Kits and&#xD;
           23andme password protected mobile app platform (GSR Dashboard) in collecting one&#xD;
           biological (saliva) sample and distributing the genetic result (using commercially&#xD;
           available results only, distributed by 23andme®), for up to 200 self-referred adult MS&#xD;
           participants. This aim is for testing the system interface only. 23andme® has their own&#xD;
           independent consent form and IRB coverage for their commercial product.&#xD;
&#xD;
        3. To estimate the percentage of registered participants that will meet eligibility&#xD;
           criteria for MS.&#xD;
&#xD;
        4. To estimate the percentage of participants that a) complete all clinical tasks; b)&#xD;
           complete all surveys; c) provide genetic information; and d) provide MRI scans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Participants willing to provide genetic and MRI data via myMS</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of participants with both genetic and MRI data available</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva samples are collected for DNA analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with a diagnosis of Multiple Sclerosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females participants with access to an iPhone 5 and above.&#xD;
&#xD;
          -  Participants willing to provide electronic consent.&#xD;
&#xD;
          -  Age 18 and above.&#xD;
&#xD;
          -  A diagnosis of MS (Polman, 2010), with dissemination in time and space. CIS&#xD;
             participants will be included if they fulfil 3 of the 4 MRI criteria for dissemination&#xD;
             in space as per Polman et al. 2010.&#xD;
&#xD;
          -  EDSS of between 0 and 8.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 18 years of age&#xD;
&#xD;
          -  Participants who do not consent to participate.&#xD;
&#xD;
          -  Participants participating in ongoing MS clinical trials with non-approved drugs.&#xD;
&#xD;
          -  Any concurrent illness, disability or clinically significant abnormality (including&#xD;
             laboratory tests) that may prevent the subject from safely completing the assessments&#xD;
             required by the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Pelletier, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keck School of Medicine of USC, University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aimslab@Usc.Edu</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Daniel Pelletier</investigator_full_name>
    <investigator_title>Professor of Neurology; Vice Chair, Clinical Research, Department of Neurology; Division Chief, Neuro-Immunology and USC Multiple Sclerosis Center</investigator_title>
  </responsible_party>
  <keyword>MS</keyword>
  <keyword>23andMe</keyword>
  <keyword>MRI</keyword>
  <keyword>Genome-wide association studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Participants will have the option to opt in or out for researchers to be able to share individual participant data (IPD) with researchers outside of USC.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

